Identifying Molecular Biomarkers Predictive of Response to Radiation Therapy in Lung Cancer
Thoracic radiation is used in ~30 percent of all lung cancer patients and thus it is important to know which patients will benefit from such therapy.
Similar to the work for available chemotherapy, we have developed radiation response profiles of a large panel of lung cancer lines and have identified lung cancers that are very sensitive and others very resistant to radiation therapy.
In conjunction with our molecular genome-wide data (mRNA, copy number, methylation) we have developed molecular biomarkers that predict survival benefit to patients with non-small cell lung cancer.
Additionally, we are evaluating the radiation-induced DNA double-strand break repair capacity in these lines in order to gain a better understanding of the causes of radiation sensitivity and resistance.
